Oruka Therapeutics, Inc. (ORKA) Stock Price & How to Invest

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies for plaque psoriasis and other inflammatory and immunology conditions. Its lead program, ORKA-001, is a half-life-extended IL-23p19 inhibitor designed for potential once-yearly dosing, and reported positive interim EVERLAST-A Phase 2a data in 2026 (roughly 63.5% of treated participants reaching PASI 100, or complete skin clearance, at Week 16). A second asset, ORKA-002, is an IL-17 antibody that entered a Phase 2 trial (ORCA-SURGE) with data expected in 2027. The pitch is best-in-class efficacy with far less frequent dosing than today's psoriasis biologics.

As a pre-revenue company, ORKA generates no product sales and burns cash funding its trials, so the stock trades on clinical milestones and sentiment rather than earnings. After an April 2026 equity raise that netted roughly $658 million, the company held well over $1 billion in cash and investments, giving it a multi-year runway. The market capitalization (several billion dollars) already prices in meaningful clinical success, which means the investment picture is a high-conviction, binary bet: strong data or approvals could drive large gains, while a trial miss or competitive setback could sharply reduce the value.

ORKA is a pre-revenue, clinical-stage biotech, so failure of a pivotal trial or a safety signal could cause severe and permanent loss of value. Interim Phase 2a results do not guarantee success in larger, longer registrational studies, and the psoriasis space is intensely competitive with established, effective biologics from much larger companies. The valuation already embeds substantial clinical optimism, leaving little margin for disappointment. The company burns tens of millions of dollars per quarter and will likely need additional capital over time, which can dilute shareholders. The stock has been highly volatile, with large swings tied to data and sentiment.

12 analysts publish price targets on ORKA, averaging $148.17 against a $96.51 price as of August 2026, or +53.5%. The published targets run from $102.00 to $200.00, a moderate spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 7 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ORKA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Oruka Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. ORKA-001 efficacy and dosing differentiation. The lead IL-23p19 antibody posted strong interim Phase 2a skin-clearance rates and is engineered for potential once-yearly dosing. The most optimistic published target, $200.00, assumes this works close to its best case.

The case against. ORKA is a pre-revenue, clinical-stage biotech, so failure of a pivotal trial or a safety signal could cause severe and permanent loss of value. The most pessimistic target, $102.00, is roughly what ORKA is worth if this bites instead.

Read the full bull and bear case on ORKA, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Oruka Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$0 (pre-revenue)
• Market cap: ~$5B+
• Cash & investments: ~$1.1B+ (pro forma after April 2026 raise)
• Full-year 2025 cash used in operations: ~$88M
• Q4 2025 cash burn: ~$23M
• Net income: Net loss (typical of clinical-stage biotech)

With no product revenue, traditional multiples like P/E do not apply, and the valuation reflects the market's estimate of ORKA-001 and ORKA-002 succeeding and reaching commercialization. The several-billion-dollar market cap sits on top of a strong cash position but assumes significant clinical and regulatory milestones are met. Investors are effectively pricing pipeline optionality, not current fundamentals.

If you want ORKA exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to ORKA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ORKA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XBI), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ORKA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ORKA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ORKA is a well-funded, single-theme clinical-stage biotech whose value hinges almost entirely on trial results and future approval, which makes it high-risk and binary rather than a steady operating business.

Whether ORKA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ORKA a buy or a sell?, and where the stock could go from here in the ORKA stock forecast.

For income investors, whether ORKA pays a dividend and how the payout looks is covered in does ORKA pay a dividend? And to weigh ORKA against a peer, read the full side-by-side comparisons: ORKA vs ABBV and ORKA vs JNJ.